{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:53:49Z","timestamp":1784908429139,"version":"3.55.0"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007404","name":"AIDS Clinical Trials","doi-asserted-by":"publisher","award":["AI068636"],"award-info":[{"award-number":["AI068636"]}],"id":[{"id":"10.13039\/100007404","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007404","name":"AIDS Clinical Trials","doi-asserted-by":"publisher","award":["1560GYD212"],"award-info":[{"award-number":["1560GYD212"]}],"id":[{"id":"10.13039\/100007404","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Nonalcoholic fatty liver disease (NAFLD) and subsequent progression to fibrosis is increasingly prevalent in people with HIV (PWH). We used noninvasive methods to stratify risk and identify associated factors of advanced fibrosis in PWH with NAFLD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective study of PWH in our clinic from 2005 to 2022. We used liver imaging or biopsy reports to identify cases of hepatic steatosis after excluding specified etiologies. We used the Fibrosis-4 (FIB-4), NAFLD Fibrosis (NFS), and body mass index, aspartate transaminase\/alanine transaminase ratio, and diabetes score scores to stratify fibrosis. We used logistic regression to identify factors associated with advanced fibrosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 3959 PWH in care, 1201 had available imaging or liver biopsies. After exclusions, 114 of 783 PWH had evidence of hepatic steatosis (14.6%). Most were male (71.1%), with a median age of 47 years, and median body mass index of 30.1\u2005kg\/m2. Approximately 24% had lean NAFLD (ie, body mass index &amp;lt; 25\u2005kg\/m2). Based on the FIB-4 and NFS, 34 (29.8%) and 36 (31.6%) had advanced fibrosis, whereas 1 in 4 had low risk of fibrosis based on FIB-4, NFS, and BARD scores. In adjusted analysis using FIB-4, advanced fibrosis was associated with age &amp;gt; 45 years (adjusted odds ratio, 6.29; 95% confidence interval, 1.93\u201320.50) and hypoalbuminemia (adjusted odds ratio, 9.45; 95% confidence interval, 2.45\u201332.52) in addition to elevated transaminases and thrombocytopenia, whereas using the NFS did not identify associations with advanced fibrosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We found 14.6% of PWH had NAFLD, with 1 in 3 having advanced fibrosis. Our study provides practical insights into fibrosis risk stratification in HIV primary care settings.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae014","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T02:05:23Z","timestamp":1704852323000},"source":"Crossref","is-referenced-by-count":7,"title":["Risk Stratification of Advanced Fibrosis in Patients With Human Immunodeficiency Virus and Hepatic Steatosis Using the Fibrosis-4, Nonalcoholic Fatty Liver Disease Fibrosis, and BARD Scores"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-1812","authenticated-orcid":false,"given":"George A","family":"Yendewa","sequence":"first","affiliation":[{"name":"Department of Medicine, Case Western Reserve University School of Medicine , Cleveland, Ohio , USA"},{"name":"Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center , Cleveland, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Khazan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Case Western Reserve University School of Medicine , Cleveland, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Case Western Reserve University School of Medicine , Cleveland, Ohio , USA"},{"name":"Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center , Cleveland, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"2024022012535453200_ofae014-B1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: from obesity to metabolic syndrome and diabetes","volume":"12","author":"Godoy-Matos","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"2024022012535453200_ofae014-B2","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.cgh.2023.01.001","article-title":"Prevalence and characteristics of nonalcoholic fatty liver disease and fibrosis in people living with HIV monoinfection: a systematic review and meta-analysis","volume":"21","author":"Kalligeros","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024022012535453200_ofae014-B3","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2012.10.001","article-title":"Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review","volume":"10","author":"White","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024022012535453200_ofae014-B4","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024022012535453200_ofae014-B5","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/QAD.0000000000001504","article-title":"Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection","volume":"31","author":"Maurice","year":"2017","journal-title":"AIDS"},{"key":"2024022012535453200_ofae014-B6","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3389\/fimmu.2020.01086","article-title":"Role of Kupffer cells in driving hepatic inflammation and fibrosis in HIV infection","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"2024022012535453200_ofae014-B7","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1189\/jlb.3HI0516-242R","article-title":"Frontline science: HIV infection of Kupffer cells results in an amplified proinflammatory response to LPS","volume":"101","author":"Mosoian","year":"2017","journal-title":"J Leukoc Biol"},{"key":"2024022012535453200_ofae014-B8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00002030-199201000-00008","article-title":"Identification and quantitation of HIV-1 in the liver of patients with AIDS","volume":"6","author":"Cao","year":"1992","journal-title":"AIDS"},{"key":"2024022012535453200_ofae014-B9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/cld.880","article-title":"The pathogenesis of liver disease in people living with human immunodeficiency virus: the emerging role of the microbiome","volume":"15","author":"Kardashian","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"2024022012535453200_ofae014-B10","first-page":"75","article-title":"Fatty liver disease in persons with HIV infection","volume":"27","author":"Seth","year":"2019","journal-title":"Top Antivir Med"},{"key":"2024022012535453200_ofae014-B11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13181-013-0325-8","article-title":"A review of the toxicity of HIV medications","volume":"10","author":"Margolis","year":"2014","journal-title":"J Med Toxicol"},{"issue":"Suppl 1","key":"2024022012535453200_ofae014-B12","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1097\/00002030-200304001-00017","article-title":"HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management","volume":"17","author":"Carr","year":"2003","journal-title":"AIDS"},{"key":"2024022012535453200_ofae014-B13","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024022012535453200_ofae014-B14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"2024022012535453200_ofae014-B15","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO)","year":"2016","journal-title":"J Hepatol"},{"key":"2024022012535453200_ofae014-B16","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2013.12.018","article-title":"Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations","volume":"60","author":"de L\u00e9dinghen","year":"2014","journal-title":"J Hepatol"},{"key":"2024022012535453200_ofae014-B17","doi-asserted-by":"crossref","first-page":"101116","DOI":"10.1016\/j.eclinm.2021.101116","article-title":"Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART)","volume":"40","author":"Bischoff","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2024022012535453200_ofae014-B18","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1086\/521857","article-title":"The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection","volume":"45","author":"Vergara","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2024022012535453200_ofae014-B19","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"2024022012535453200_ofae014-B20","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/gut.2007.146019","article-title":"Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease","volume":"57","author":"Harrison","year":"2008","journal-title":"Gut"},{"key":"2024022012535453200_ofae014-B21","doi-asserted-by":"crossref","first-page":"ofac279","DOI":"10.1093\/ofid\/ofac279","article-title":"Assessment of noninvasive markers of steatosis and liver fibrosis in human immunodeficiency virus-monoinfected patients on stable antiretroviral regimens","volume":"9","author":"Busca","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024022012535453200_ofae014-B22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.21037\/tgh.2019.11.14","article-title":"Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease","volume":"5","author":"Altamirano","year":"2020","journal-title":"Transl Gastroenterol Hepatol"},{"key":"2024022012535453200_ofae014-B23","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD)","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"2024022012535453200_ofae014-B24"},{"key":"2024022012535453200_ofae014-B25","author":"Centers for Disease Control and Prevention (2023)"},{"issue":"Suppl 1","key":"2024022012535453200_ofae014-B26","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.2337\/dc14-S081","article-title":"Diagnosis and classification of diabetes mellitus","volume":"37","author":"American Diabetes Association (2018)","year":"2014","journal-title":"Diabetes Care"},{"key":"2024022012535453200_ofae014-B27","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2024022012535453200_ofae014-B28","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"2024022012535453200_ofae014-B29","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"2024022012535453200_ofae014-B30","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.cgh.2020.08.017","article-title":"Prevalence of fatty liver disease and fibrosis detected by transient elastography in adults in the United States, 2017\u20132018","volume":"19","author":"Kim","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024022012535453200_ofae014-B31","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/apt.13052","article-title":"Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study","volume":"41","author":"Vodkin","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2024022012535453200_ofae014-B32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MCG.0b013e318264181d","article-title":"Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse","volume":"47","author":"Sterling","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"2024022012535453200_ofae014-B33","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1097\/QAD.0000000000001241","article-title":"Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients","volume":"30","author":"Vuille-Lessard","year":"2016","journal-title":"AIDS"},{"key":"2024022012535453200_ofae014-B34","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/589294","article-title":"Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors","volume":"47","author":"Guaraldi","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2024022012535453200_ofae014-B35","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/jcm7120562","article-title":"Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients","volume":"7","author":"Denkmayr","year":"2018","journal-title":"J Clin Med"},{"key":"2024022012535453200_ofae014-B36","doi-asserted-by":"crossref","first-page":"e694","DOI":"10.1093\/cid\/ciaa430","article-title":"Prevalence, predictors, and severity of lean nonalcoholic fatty liver disease in patients living with human immunodeficiency virus","volume":"71","author":"Cervo","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024022012535453200_ofae014-B37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep4.1124","article-title":"Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study","volume":"2","author":"Hagstr\u00f6m","year":"2017","journal-title":"Hepatol Commun"},{"key":"2024022012535453200_ofae014-B38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ajg.2016.318","article-title":"Clinical and metabolic characterization of lean Caucasian subjects with non-alcoholic fatty liver","volume":"112","author":"Feldman","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2024022012535453200_ofae014-B39","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/hep4.1529","article-title":"Genome-wide association study of lean nonalcoholic fatty liver disease suggests human leukocyte antigen as a novel candidate locus","volume":"4","author":"Yoshida","year":"2020","journal-title":"Hepatol Commun"},{"key":"2024022012535453200_ofae014-B40","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.cgh.2018.12.031","article-title":"NASH Clinical Research Network. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024022012535453200_ofae014-B41","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut"},{"issue":"Suppl 1","key":"2024022012535453200_ofae014-B42","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S2352-3018(22)00069-8","article-title":"Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway","volume":"9","author":"Sebastiani","year":"2022","journal-title":"Lancet HIV"},{"key":"2024022012535453200_ofae014-B43","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/cncr.22242","article-title":"Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma","volume":"107","author":"Lu","year":"2006","journal-title":"Cancer"},{"key":"2024022012535453200_ofae014-B44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00535-018-1494-7","article-title":"Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients","volume":"54","author":"Shima","year":"2019","journal-title":"J Gastroenterol"},{"key":"2024022012535453200_ofae014-B45","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/j.1440-1746.2006.04447.x","article-title":"Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease","volume":"21","author":"Kaneda","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"2024022012535453200_ofae014-B46","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/hepr.13628","article-title":"Artificial intelligence\/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"51","author":"Okanoue","year":"2021","journal-title":"Hepatol Res"},{"key":"2024022012535453200_ofae014-B47","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2147\/DMSO.S356497","article-title":"Association between the risk of non-alcoholic fatty liver disease in patients with type 2 diabetes and chronic kidney disease","volume":"15","author":"Zhao","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2024022012535453200_ofae014-B48","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2147\/CIA.S65382","article-title":"Nonalcoholic fatty liver disease (NAFLD)\u2014a new factor that interplays between inflammation, malnutrition, and atherosclerosis in elderly hemodialysis patients","volume":"9","author":"Mikolasevic","year":"2014","journal-title":"Clin Interv Aging"},{"key":"2024022012535453200_ofae014-B49","doi-asserted-by":"crossref","first-page":"e26835","DOI":"10.1097\/MD.0000000000026835","article-title":"Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease","volume":"100","author":"Kawaguchi","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2024022012535453200_ofae014-B50","first-page":"CD008623","article-title":"Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"(12)","author":"Eslami","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2024022012535453200_ofae014-B51","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","article-title":"A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"43","author":"Nelson","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"2024022012535453200_ofae014-B52","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.3390\/nu14214673","article-title":"Once-weekly subcutaneous semaglutide improves fatty liver disease in patients with type 2 diabetes: a 52-week prospective real-life study","volume":"14","author":"Volpe","year":"2022","journal-title":"Nutrients"},{"key":"2024022012535453200_ofae014-B53","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/hep.32294","article-title":"Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease","volume":"76","author":"Zhang","year":"2022","journal-title":"Hepatology"},{"key":"2024022012535453200_ofae014-B54","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1365-2036.2010.04467.x","article-title":"Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis","volume":"32","author":"Rakoski","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"2024022012535453200_ofae014-B55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed Rep"},{"key":"2024022012535453200_ofae014-B56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD","volume":"107","author":"Chavez C","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2024022012535453200_ofae014-B57","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"2024022012535453200_ofae014-B58","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"NN9931-4492 investigators. Semaglutide 2.4\u2005mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024022012535453200_ofae014-B59","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2024022012535453200_ofae014-B60","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3390\/cells10051212","article-title":"Liver fibrosis during antiretroviral treatment in HIV-infected individuals. Truth or tale?","volume":"10","author":"Bakasis","year":"2021","journal-title":"Cells"},{"key":"2024022012535453200_ofae014-B61","doi-asserted-by":"crossref","first-page":"493413","DOI":"10.1155\/2013\/493413","article-title":"Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome","volume":"2013","author":"P\u00e9rez-Matute","year":"2013","journal-title":"Oxid Med Cell Longev"},{"key":"2024022012535453200_ofae014-B62","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI200319451","article-title":"Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance","volume":"112","author":"Xu","year":"2003","journal-title":"J Clin Invest"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae014\/55278770\/ofae014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/2\/ofae014\/56714810\/ofae014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/2\/ofae014\/56714810\/ofae014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T12:54:35Z","timestamp":1708433675000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae014\/7513263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae014","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2024,1,9]]},"article-number":"ofae014"}}